Gilead Sciences was founded in 1987 in Foster City, California. In 25 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Our current research and development effort includes more than 75 Phase 2 and 3 clinical studies evaluating compounds with the potential to become the next generation of innovative therapies for HIV, hepatitis, serious respiratory, cardiovascular and metabolic conditions, cancer and inflammation. In 2012, Gilead’s annual revenues reached approximately $9.7 billion.
Through our own research and partnerships with universities, medical research institutions and global pharmaceutical leaders, Gilead is rapidly and efficiently making scientific and clinical advancements that raise the standard for new therapeutics that treat life-threatening diseases. Our research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, cardiovascular and respiratory conditions and oncology and inflammation.
The Gilead Foundation, a non-profit organization established in 2005, seeks to improve the health and well-being of underserved communities around the world. Our giving focuses on expanding access to HIV and hepatitis education, outreach, prevention and health services.
The Gilead Foundation provides grants to programs in the United States and internationally.